Akebia Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Akebia Therapeutics has a total shareholder equity of $-30.6M and total debt of $90.7M, which brings its debt-to-equity ratio to -296.7%. Its total assets and total liabilities are $241.7M and $272.3M respectively.
Key information
-296.7%
Debt to equity ratio
US$90.74m
Debt
| Interest coverage ratio | n/a |
| Cash | US$42.93m |
| Equity | -US$30.58m |
| Total liabilities | US$272.29m |
| Total assets | US$241.70m |
Recent financial health updates
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Akebia highlights late-stage vadadustat kidney disease study results
Apr 28Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?
Mar 31Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?
Mar 10Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?
Mar 10Financial Position Analysis
Short Term Liabilities: AKBA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AKBA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AKBA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AKBA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKBA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AKBA has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 5.6% each year.